CDT Equity Plans 1-for-10 Reverse Stock Split to Preserve Nasdaq Listing
CDT is trading near its 52-week low of $0.34 (5.3% below the low).
Summary
CDT Equity is enacting a 1-for-10 reverse stock split to stay listed on Nasdaq, reducing shares to ~631,077 but leaving authorized shares at 250 million — a setup for extreme future dilution against a backdrop of near-zero cash and a going concern warning.
Key Events · Corporate Governance and Compliance · CDT
-
1-for-10 Reverse Stock Split
Effective July 17, 2026, every 10 shares of CDT common stock will be combined into one share, reducing outstanding shares to approximately 631,077. The move is aimed at regaining compliance with Nasdaq's minimum bid price requirement.
-
Massive Dilution Headroom Created
Authorized common shares remain at 250 million post-split, meaning the company can issue up to 249.4 million additional shares — nearly 400 times the current outstanding count. This sets the stage for extreme dilution if the company taps its existing $76 million ATM or issues more convertible debt.
-
Cash Crisis and Going Concern
The reverse split comes one day after CDT's Q1 2026 filing disclosed only $97,000 in cash and a going concern warning. The company is reliant on dilutive financing to survive, and the reverse split does not address the underlying cash burn.
-
Nasdaq Compliance Lifeline
The reverse split is designed to lift the stock price above Nasdaq's $1.00 minimum bid requirement. Trading on a split-adjusted basis begins July 20, 2026. Failure to maintain listing would further impair the company's ability to raise capital.
Analysis · CDT · Life Sciences
To regain compliance with Nasdaq's minimum bid price rule, CDT Equity is implementing a 1-for-10 reverse stock split effective July 17, 2026. The move will shrink outstanding shares to roughly 631,077, but the authorized share count stays at 250 million — creating enormous headroom for future dilution. This action comes just one day after the company's Q1 filing revealed a cash crisis with only $97,000 on hand and a going concern warning. While the reverse split is a survival tactic to keep the stock listed, it does nothing to address the underlying cash burn. With the ATM program already expanded to $76 million and a history of highly dilutive convertible loans, the post-split share structure sets the stage for massive additional dilution that could wipe out existing holders.
At the time of this filing, CDT was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.34 to $468.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.